首页> 外文期刊>Obstetrical and gynecological survey >High Gonadotropin Dosage Does Not Affect Euploidy and Pregnancy Rates in IVF PGS Cycles With Single Embryo Transfer
【24h】

High Gonadotropin Dosage Does Not Affect Euploidy and Pregnancy Rates in IVF PGS Cycles With Single Embryo Transfer

机译:高促性腺激素剂量不会影响IVF PGS循环的欧洲倍性和妊娠率,单一胚胎转移

获取原文
获取原文并翻译 | 示例
           

摘要

The most effective and reliable method for embryo selection in in vitro fertilization (IVF) cycles is preimplantation genetic screening (PGS). There is a significant decrease in euploidy and blastulation rates with increasing maternal age. To obtain an adequate number of follicles in women of advanced maternal age, the average gonadotropin dosage administered during controlled ovarian stimulation in IVF cycles is significantly increased. However, there are conflicting reports and lack of guidance regarding gonadotropin dosing. Some studies have reported that high gonadotropin dosages have adverse effects on oocyte quality and clinical pregnancy rates, but several recent studies have refuted those findings. Few human gonadotropin doseresponse trials have been performed, and the effect of high gonadotropin doses is still poorly understood. The aim of this retrospective study was to determine whether different dosages of gonadotropins affect euploidy and pregnancy rates in IVF PGS cycles with single embryo transfer. The study was conducted between January 2013 and January 2017. To identify differences in euploidy and clinical pregnancy rates, SNP (single-nucleotide polymorphism) PGS outcome data were obtained from blastocysts biopsied on days 5 or 6. A total of 794 cycles of IVF treatment with PGS followed by 651 single frozen embryo transfers in 506 patients were included in the study. The average maternal age was 37 years. A total of 4034 embryos were analyzed for euploidy rates (5.1 +/- 3.76 per case). After biopsy, all embryos were vitrified, and euploid embryos were subsequently thawed for a hormone replacement frozen embryo transfer cycle. All patient cycles were analyzed by (1) total gonadotropin dosage ( 3000, 3000-5000, and 5000 IU), (2) number of eggs retrieved (1-5, 5-10, 10-15, and 15 eggs), and (3) patient's age ( 35, 35-37, 38-40, and = 41 years). Clinical pregnancy was defined by the presence of a fetal heartbeat at 6 to 7 weeks of gestation, and an ongoing pregnancy was defined as a viable pregnancy after 8 weeks' gestation. No significant difference was found in euploidy rates regardless of the total dosage of gonadotropins used or the number of eggs retrieved. In patients younger than 35 years (187 IVF cycles), euploidy rates ranged from 62.3% (when 3000 IU was used in the IVF cycle) to 67.5% (when 5000 IU was used in the IVF cycle; odds ratio [OR], 0.862; 95% confidence interval [CI], 0.687-1.082; P = 0.2), and rates ranged from 69.5% (when 1-5 eggs were retrieved) to 60.0% (when 15 eggs were retrieved) (OR, 0.658; 95% CI, 0.405-1.071; P = 0.09). Similar data were obtained in patients of advanced maternal age (= 41 years of age, 189 IVF cycles). When this age group was analyzed by total dosage of gonadotropins used in the IVF cycle, euploidy rates ranged from 30.7% to 26.4% (OR, 0.811; 95% CI, 0.452-1.454; P = 0.481), and when assessed by the total number of eggs retrieved, rates ranged from 40.0% to 30.7% (OR, 0.531; 95% CI, 0.204-1.384; P = 0.19). Ongoing pregnancy rates were not significantly different within particular age groups and also between different age groups regardless of the total dosage of gonadotropins administered: rates ranged from 63.6% ( 3000 IU, 35 years of age) to 54.8% ( 5000 IU, = 41 years of age) (OR, 0.696; 95% CI, 0.310-1.565; P = 0.38). Study limitations included the retrospective nature of the study and heterogeneity of patients.
机译:体外施肥中最有效和可靠的胚胎选择方法(IVF)循环是临床遗传筛查(PGS)。随着产妇年龄的增加,欧洲倍性和麻布率显着降低。为了获得高级孕产妇年龄的女性足够数量的卵泡,IVF循环中受控卵巢刺激期间施用的平均促进促淋促毒素剂量显着增加。但是,有关于促性腺激素给药的矛盾的报告和缺乏指导。一些研究报告称,高促性腺激素剂量对卵母细胞质量和临床妊娠率的不利影响,但最近的几项研究驳斥了这些结果。已经进行了很少的人类促性腺激素屈服试验,并且高促性腺激素剂量的影响仍然很差。该回顾性研究的目的是确定不同剂量的促性腺激素是否影响IVF PGS循环中的欧洲倍性和妊娠率,单胚胎转移。该研究于2013年1月至2017年1月进行。为了鉴定欧洲稀倍性和临床妊娠率的差异,SNP(单核苷酸多态性)PGS结果数据是从第5天或6天的胚泡中获得的。总共794个循环的IVF治疗使用PGS,然后在506名患者中纳入651个单一冷冻胚胎转移。平均母亲年龄为37岁。分析总共4034个胚胎,用于欧洲倍性率(每种情况下5.1 +/- 3.76)。在活组织检查之后,将所有胚胎塑性,随后随后解冻Euproid胚胎以进行激素置换冷冻胚胎转移循环。通过(1)分析所有患者循环(1)总促性腺激素剂量(& 3000,3000,& 5000 IU),(2)检索卵数(1-5,5-10,10-15,和&gt ; 15个鸡蛋),和(3)患者的年龄(& 35,35-37,38-40,= 41岁)。临床怀孕由妊娠6至7周的胎儿心跳存在,并且在8周妊娠后,持续的妊娠被定义为可行的妊娠。无论使用促性腺激素的总剂量或所检索的卵数,欧洲倍细速率没有显着差异。在35岁以下的患者(187次IVF循环)中,欧洲倍细率范围为62.3%(当IVF循环中使用时使用时)至67.5%(当IVF循环中使用时使用& 5000 IU;赔率比例[或],0.862; 95%置信区间[CI],0.687-1.082; p = 0.2),并且速率范围为69.5%(当检索1-5个鸡蛋时)至60.0%(当检索时& 15蛋)(或,0.658; 95%CI,0.405-1.071; p = 0.09)。在先进的孕产妇年龄(= 41岁,189年IVF循环)中获得了类似的数据。当通过IVF循环中使用的促性腺激素的总剂量分析该年龄组时,欧倍体率范围为30.7%至26.4%(或0.811; 95%CI,0.452-1.454; P = 0.481),并在总数评估时检索的鸡蛋数,速率范围为40.0%至30.7%(或0.531; 95%CI,0.204-1.384; P = 0.19)。在特定年龄组中,在特定年龄组中,不同年龄组的持续妊娠率没有明显不同,无论施用的促性腺激素的总剂量如何:速率范围为63.6%(& 35岁,35岁)至54.8%(& 5000 IU,= 41岁)(或0.696; 95%CI,0.310-1.565; P = 0.38)。研究限制包括患者研究和异质性的回顾性质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号